- cafead   Mar 02, 2019 at 12:52: PM
via Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.
article source
article source